Continuous inspection readiness means
the auditor never catches you off guard.
Compliance Group commits to zero major audit observations — with no-cost remediation if any occur. We back this with CLAiRE AI Agentic Platform's continuous monitoring, 25+ years in the audit room, and a team of named expert advisors covering Regulatory Intelligence, AI Governance, Digital CSA, and Audit & Inspection Readiness.
If an FDA inspection were scheduled for next Thursday — not in 90 days, Thursday — what would the 48 hours before their arrival look like for your team? For most organizations, the honest answer involves a level of scrambling that reveals exactly how much of inspection readiness depends on people working overtime rather than systems working continuously.
What inspection readiness looks like as a daily state, not a periodic sprint.
Evidence assembled in minutes, not days
CLAiRE AI Agentic Platform continuous collection means audit packages are always current. The 90-day pre-inspection sprint collapses to 90 minutes of final review.
Findings surface before the auditor arrives
CLAiRE Continuous Monitoring identifies deviations against corporate procedures in real time. Gaps are closed proactively — not discovered under inspection pressure.
Your team is briefed, not scrambling
Mock audit experience and pre-inspection preparation replace the war room. Your team knows the narrative. The evidence supports it.
Post-inspection response is structured and guaranteed
When Form 483 observations arrive, Compliance Group's structured response framework activates — with our zero major observations commitment meaning no-cost remediation if we fall short.
The 90-day pre-inspection sprint is expensive, exhausting, and increasingly inadequate.
Most life sciences organizations treat inspection readiness as a periodic project. That model worked when regulatory expectations were more predictable. It doesn't work today.
The scramble reveals the architecture problem
The 90-day sprint reveals gaps that should have been addressed continuously. By the time they surface pre-inspection, closing them under time pressure is expensive and creates new risk.
AI governance questions are arriving without warning
FDA inspectors are including AI governance questions in routine inspections. Organizations without documented frameworks are getting observations with no formal notification that this is coming.
QMSR creates new audit evidence requirements
The Quality Management System Regulation replaces the old Part 820 framework with ISO 13485-aligned requirements. Many organizations haven't updated their audit evidence approach to match.
EU GMP Annex 11 expectations have evolved
Annex 11 inspections now include AI governance, audit trail completeness, and CSA methodology questions that weren't common five years ago.
Form 483 responses are under more scrutiny
FDA reviewers are evaluating the quality of CAPA responses more critically. A weak response extends the inspection cycle and can escalate to a Warning Letter.
Pre-commercial organizations face their first inspection unprepared
Scaling biotechs and device companies approaching their first FDA or EU GMP inspection with compliance programs built for a smaller organization face a readiness gap that can delay approvals.
Continuous readiness, pre-inspection preparation, post-inspection response — and a zero-observation commitment.
CLAiRE AI Agentic Platform — Continuous Readiness
100% audit trail review daily, Continuous Monitoring for procedure deviations, Integrated Compliance Assessments across GxP and Part 11, and real-time Microsoft Teams alerting. Audit readiness is a standing capability, not a project.
Pre-Inspection Preparation
Gap assessment against current FDA/EU GMP/ISO 13485 expectations, evidence preparation, team briefing and mock audit facilitation, AI governance documentation review, and narrative preparation. 300+ GxP system knowledgebase included — no build-from-scratch.
Post-Inspection Response — With Guarantee
For organizations with recent Form 483 observations or Warning Letter citations: root cause analysis, CAPA design and implementation, and regulatory communication support. Zero major observations commitment means if Compliance Group falls short, remediation is at no cost.
AI Governance Inspection Readiness
CLAiRE AI Agentic Platform evidence packages, ISO/IEC 42001 posture documentation, model risk assessment summaries, and human oversight mechanism documentation — formatted specifically for FDA AI governance inspection questions.
Every Inspection Readiness engagement is powered by CLAiRE AI Agentic Platform — Audit Trail Review, Continuous Monitoring, and Integrated Compliance Assessments working together. CLAiRE is what converts periodic inspection readiness into a standing capability with a zero-observation commitment behind it.
Book a Free AI Readiness Assessment.
45 minutes with a senior expert—not a sales rep. Written risk brief included. No commitment. You walk away knowing exactly where your biggest regulatory exposure sits.
Book Your Free Assessment